Skip to main content
Premium Trial:

Request an Annual Quote

Fisher Biosciences and Alfa Laval to Provide Disposable Bioprocessing Systems for Haemacure

NEW YORK, Dec. 14 (GenomeWeb News) - Fisher Biosciences, through its HyClone business, will partner with Alfa Laval to provide Haemacure with single-use bioprocessing systems, the company said today.

 

The bioprocessing systems are marketed and sold by Alfa Laval under an exclusive agreement with HyNetics, a three-year joint venture between HyClone and Alfa Laval.

 

The systems will be installed in Haemacure's Sarasota, Fla. manufacturing facility for Hemaseel biological adhesives. This will be one of the first major installations of HyNetics technology for large-scale bioprocessing.

 

Under the agreement, Alfa Laval will provide all of the detailed engineering for the facility as well as select the production equipment. The core bioprocessing equipment will be the HyNetics single-use mixing technology.

 

HyClone will provide Haemacure with its proprietary disposable BioProcess Containers as well as other disposable components that complement the HyNetics system.

 

The disposable bioprocessing system will allow Haemacure to "establish and operate a very cost-efficient facility," said Marc Paquin, Haemacure's president and chief executive officer, in a statement.

 

Financial details were not disclosed.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.